Pre-transplant disease burden rather than age or donor type was associated with survival of hematopoietic cell transplantation for elderly patients with acute myeloid leukemia
Rui Ma,Yi Liao,Xiao-Hui Zhang,Lan-Ping Xu,Yu Wang,Xiao-Dong Mo,Meng LV,Yuan-Yuan Zhang,Chen-Hua Yan,Yu-Hong Chen,Yao Chen,Jing-Zhi Wang,Feng-Rong Wang,Ting-Ting Han,Jun-Kong,Zhi-Dong Wang,Wei Han,Huan Chen,Yun He,Zheng-Li Xu,Feng-Mei Zheng,Hai-Xia Fu,Kai-Yan Liu,Xiao-Jun Huang,Yu-Qian Sun
DOI: https://doi.org/10.1038/s41409-024-02457-2
2024-11-07
Bone Marrow Transplantation
Abstract:Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the best treatment for patients with intermediate- to high-risk acute myeloid leukemia (AML) for prolonged disease control or cure [1]. In the early days, elderly patients (≥50 years old) were usually considered not eligible for allo-HSCT due to increased morbidity and mortality. With the development of tailormade conditioning regimens such as reduced intensity conditioning (RIC), coupled with improvement in supportive care and more accurate HLA typing, allo-HSCT have been broadened to the application in elderly patients [2]. However, numerous barriers remain. Although there have been studies focusing on allo-HSCT in elderly patients [3, 4], the factors influencing transplant outcomes remain controversial, compromising clinical decision-making. Furthermore, studies on elderly patients receiving haploidentical hematopoietic stem cell transplantation (haplo-HSCT) remain scarce. In the current study, we aimed to identify the factors related to transplant outcomes, in order to provide clues for future optimization of candidate selection and transplant protocols in elderly patients with AML. A total of 199 elderly patients (≥50 years old) with AML who underwent allo-HSCT at Peking University People's Hospital between June 2015 and November 2021 were enrolled in this retrospective study. The AML risk category was assessed according to the European Leukemia Net recommendations [2]. The burden of comorbidities before HSCT was evaluated using the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) [1]. The standard conditioning regimen consisted of cytarabine (Ara-C, 4 g/m 2 /day, –9 day), busulfan (Bu, 3.2 mg/kg/day, –8 to –6 days), cyclophosphamide (Cy, 1.8 g/m 2 /day, –5 to –4 days), semustine (250 mg/m 2 , –3 day), and rabbit anti-thymocyte globulin (ATG, 2.5 mg/kg, –5 to –2 days; Sanofi, France). The RIC consisted of Ara-C (2 g/m 2 /day, –10 to –9 days), Bu (3.2 mg/kg/day, –8 to –6 days), fludarabine (Flu, 30 mg/m 2 /day, –6 to –2 days), Cy (1.0 g/m 2 /day, –5 to –4 days), semustine (250 mg/m 2 , -3 day), and ATG (2.5 mg/kg, -5 to -2 days). Neutrophil and platelet engraftment was defined as previously described [5]. Both acute and chronic graft-versus-host disease (GVHD) were graded according to international criteria [6]. Relapse, non-relapse mortality (NRM), leukemia-free survival (LFS) and overall survival (OS) were defined according to the literature [7].
oncology,immunology,hematology,transplantation